MDT Stock Analysis: Medtronic | NYSE
Medical Devices | NYSE, USA | Market Cap: 102.570m USD | 12M Return: -7.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 866M
EPS Trend: 76.2%
Qual. Beats: 0
Rev. Trend: 97.3%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Medtronic plc (NYSE: MDT) is a global medical device company founded in 1949 and headquartered in Galway, Ireland. It develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients across the United States, Ireland, and international markets.
The company operates through four main business segments: Cardiovascular Portfolio (offering pacemakers, defibrillators, cardiac ablation products, heart valves, and endovascular stent grafts), Neuroscience Portfolio (including spinal cord stimulation, brain modulation systems, drug infusion systems, and the Accurian nerve ablation system), Medical Surgical Portfolio (covering surgical stapling, robotic-assisted surgery, hernia devices, and patient monitoring products), and a Diabetes Operating Unit (providing insulin pumps, continuous glucose monitoring systems, and the InPen smart insulin pen).
Medtronic competes in the Health Care Equipment sub-industry within the broader Health Care sector, a space dominated by large multinational firms developing capital-intensive, regulated medical technologies. Its diversified portfolio spans chronic disease management, surgical solutions, and neuromodulation, with products sold across multiple medical specialties including cardiology, neurology, orthopedics, and endocrinology.
- MiniMed 780G adoption fuels Diabetes segment growth
- Hugo robot launches compete with Intuitive Surgical
- TAVR market share faces pressure from Edwards Lifesciences
| Net Income: 4.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.18 > 1.0 |
| NWC/Revenue: 36.10% < 20% (prev 32.61%; Δ 3.50% < -1%) |
| CFO/TA 0.08 > 3% & CFO 7.33b > Net Income 4.80b |
| Net Debt (18.8b) to EBITDA (9.72b): 1.93 < 3 |
| Current Ratio: 2.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago 0.03% < -2% |
| Gross Margin: 65.02% > 18% (prev 65.31%; Δ -0.30% > 0.5%) |
| Asset Turnover: 39.37% > 50% (prev 36.58%; Δ 2.79% > 0%) |
| Interest Coverage Ratio: 9.58 > 6 (EBIT TTM 6.85b / Interest Expense TTM 715.0m) |
| A: 0.14 (Total Current Assets 24.8b - Total Current Liabilities 11.7b) / Total Assets 93.0b |
| B: 0.35 (Retained Earnings 32.6b / Total Assets 93.0b) |
| C: 0.07 (EBIT TTM 6.85b / Avg Total Assets 92.4b) |
| D: 1.15 (Book Value of Equity 49.5b / Total Liabilities 43.0b) |
| Altman-Z'' = 3.78 = AA |
| DSRI: 0.94 (Receivables 6.64b/6.51b, Revenue 36.4b/33.5b) |
| GMI: 1.00 (GM 65.31% / 65.02%) |
| AQI: 0.98 (AQ_t 0.65 / AQ_t-1 0.67) |
| SGI: 1.08 (Revenue 36.4b / 33.5b) |
| TATA: -0.03 (NI 4.80b - CFO 7.33b) / TA 93.0b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 01, 2026, the stock is trading at USD 78.23 with a total of 7,061,300 shares traded. Over the past week, the price has changed by -2.10%, over one month by +6.70%, over three months by -8.90% and over the past year by -7.34%.
Current recommended Stop Loss: 75.80 (which is 3.1% or 1.3 ATR below the current price).
Medtronic has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy MDT.
- StrongBuy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 98 | 25.3% |
P/E Trailing = 21.4826
P/E Forward = 13.5135
P/S = 2.8344
P/B = 2.0838
P/EG = 1.5894
Revenue TTM = 36.4b USD
EBIT TTM = 6.85b USD
EBITDA TTM = 9.72b USD
Long Term Debt = 26.1b USD (from longTermDebt, last quarter)
Short Term Debt = 1.79b USD (from shortTermDebt, last quarter)
Debt = 28.0b USD (from shortLongTermDebtTotal, last quarter) + Leases 60.0m
Net Debt = 18.8b USD (calculated: Debt 28.0b - CCE 9.22b)
Enterprise Value = 121b USD (103b + Debt 28.0b - CCE 9.22b)
Interest Coverage Ratio = 9.58 (Ebit TTM 6.85b / Interest Expense TTM 715.0m)
EV/FCF = 22.37x (Enterprise Value 121b / FCF TTM 5.43b)
FCF Yield = 4.47% (FCF TTM 5.43b / Enterprise Value 121b)
FCF Margin = 14.92% (FCF TTM 5.43b / Revenue TTM 36.4b)
Net Margin = 13.20% (Net Income TTM 4.80b / Revenue TTM 36.4b)
Gross Margin = 65.02% ((Revenue TTM 36.4b - Cost of Revenue TTM 12.7b) / Revenue TTM)
Gross Margin QoQ = 75.86% (prev 64.89%)
Tobins Q-Ratio = 1.30 (Enterprise Value 121b / Total Assets 93.0b)
Interest Expense / Debt = 2.55% (Interest Expense 715.0m / Debt 28.0b)
Taxrate = 21.17% (1.30b / 6.14b)
NOPAT = 5.40b (EBIT 6.85b * (1 - 21.17%))
Current Ratio = 2.13 (Total Current Assets 24.8b / Total Current Liabilities 11.7b)
Debt / Equity = 0.57 (Debt 28.0b / totalStockholderEquity, last quarter 49.5b)
Debt / EBITDA = 1.93 (Net Debt 18.8b / EBITDA 9.72b)
Debt / FCF = 3.46 (Net Debt 18.8b / FCF TTM 5.43b)
Total Stockholder Equity = 48.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.20% (Net Income 4.80b / Total Assets 93.0b)
RoE = 9.85% (Net Income TTM 4.80b / Total Stockholder Equity 48.7b)
RoCE = 9.15% (EBIT 6.85b / Capital Employed (Equity 48.7b + L.T.Debt 26.1b))
RoIC = 6.64% (NOPAT 5.40b / Invested Capital 81.3b)
WACC = 5.61% (E(103b)/V(131b) * Re(6.59%) + D(28.0b)/V(131b) * Rd(2.55%) * (1-Tc(0.21)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -24.44 | Cagr: -1.47%
[DCF] Terminal Value 76.04% ; FCFF base≈5.33b ; Y1≈5.56b ; Y5≈6.35b
[DCF] Fair Price = 61.87 (EV 98.0b - Net Debt 18.8b = Equity 79.2b / Shares 1.28b; r=8.35% [WACC [floored]]; 5y FCF grow 4.65% → 2.50% )
EPS Correlation: 76.20 | EPS CAGR: 2.32% | SUE: -0.72 | # QB: 0
Revenue Correlation: 97.27 | Revenue CAGR: 4.84% | SUE: 3.20 | # QB: 4
EPS current Quarter (2026-07-31): EPS=1.39 | Chg30d=+0.52% | Revisions=+18% | Analysts=24
EPS next Quarter (2026-10-31): EPS=1.35 | Chg30d=-5.80% | Revisions=-83% | Analysts=24
EPS current Year (2027-04-30): EPS=5.95 | Chg30d=-1.89% | Revisions=-86% | GrowthEPS=+7.6% | GrowthRev=+6.9%
EPS next Year (2028-04-30): EPS=6.41 | Chg30d=-1.96% | Revisions=-78% | GrowthEPS=+7.7% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -86%